The Tipping Point in Psychiatry: 2025’s Breakthroughs and the Road to 2026

2025 marked a true tipping point in functional and precision psychiatry, as a wave of high-quality research moved biological, nutritional, and metabolic drivers of mental health from the margins to the center of scientific and clinical conversation. As we look toward 2026, the momentum is clear: a more personalized, evidence-based, and integrative model of care is no longer emerging—it is taking shape.

The scientific evaluation of biomedical contributions to psychiatric disorders continues to make headway, and there are exciting developments in 2025 that expand our evidence base in this much-needed area. For years, this type of research was not robust due to a lack of financial incentive to study low-cost interventions. Even research completed in this area was often invisible and continues to be invisible to traditionally trained psychiatric providers. In general, we know that there is a long lag time for research findings to influence traditional clinical practice, yet the public is demanding and seeking out providers who understand the bigger picture, which includes genetics, nutrition, and metabolic, inflammatory, and immune contributions to mental health. Functional Medicine, Integrative Psychiatry, and Precision Psychiatry are the new frontiers, and practitioners who expand their knowledge in this arena will keep pace with the future. Several major journals, including JAMA  Psychiatry  (1) and Molecular Psychiatry, published editorials this year calling for a paradigm shift.  “The time has come for global stakeholders to align research efforts to work toward integrating symptomatic, biological, and behavioral information into the definition of mental disorders to advance the development of effective treatments.” (2)

Psychiatry Redefined is committed to advancing the training of practitioners with evidence-based clinical education to support this paradigm shift and roadmap to precision psychiatry.

We begin with selected 2025 publications that advance precision and functional psychiatry, first highlighting key review articles and then exploring more narrowly focused studies. We hope you can see the momentum we feel here at Psychiatry Redefined.

Serotonin System

This is a must-read article to understand the complexities and current database for the effect of nutrition on the serotonin system, which is involved in mood, anxiety, sleep, obesity, IBS, and OCD.  Tang J. et al (3) summarize the effect of micronutrients, macronutrients, minerals, phytochemicals, and gut microbiota on serotonin synthesis and availability in the CNS. The clinical implications for treatment of depression, sleep, eating disorders, obesity, and IBS are reviewed. The current knowledge gaps are outlined, with the suggestion that genotyping for specific SNPs will move this forward toward even greater precision in treatment recommendations.

Curcumin

This excellent review by Croner, L. et al (4) discusses not only the potential role of curcumin in treating depression, but it is also a deep dive into the complex pathophysiology of depression and gives insight into why the unidimensional nature of most traditional medications all too often has limited efficacy. As a consequence, treatment efficacy is likely to occur from therapies that target multiple mechanisms. Since curcumin affects a wide range of targets and mechanisms, it may find a place as an augmentation treatment through its diverse mechanisms. Given its major anti-inflammatory properties, curcumin could also be of use in a subset of patients with depression with underlying high inflammation.

LITHIUM

The most potentially paradigm-shifting study of the year is the study by Aron L. et al on Lithium Deficiency and the onset of Alzheimer’s disease. (5)  This research is groundbreaking and has the potential to fundamentally modify our approach to MCI and Alzheimer’s disease. Post-mortem brain evaluations of individuals with mild cognitive impairment or Alzheimer’s disease identified lithium as the only deficient mineral, a deficiency that appears to result in part from amyloid plaques binding and sequestering lithium, thereby reducing its availability to surrounding healthy brain tissue. In a mouse model, dietary lithium depletion caused increased amyloid and tau phosphorylation, loss of synapses, axons, and myelin, and accelerated memory loss. Replacement with lithium orotate compared to lithium carbonate prevented pathological changes and restored memory.

MICRONUTRIENTS

Magnesium

Magnesium is one of the most common nutritional deficiencies in multiple disorders, including ADHD, anxiety, and depression. It is often overlooked because it is difficult to measure accurately in blood. Adding to the well-established database on Magnesium, in a randomized clinical trial of adults with severe depression, Jahan MW et al found supplementation of Escitalopram with Magnesium Oxide 365 mg per day was significantly more effective in reducing depression than the drug alone. 64 % in the combination arm, compared to 36% in the drug alone group, achieved a post-treatment score indicating no or minimal depressive symptoms. (6)  Raghuwanshi K, et al. found both a statistically significant negative correlation between serum magnesium levels and depression severity and suicidal behavior scores in 200 adults with MDD. (7)

Zinc  

Zinc supplementation has been associated with improvement of depression. Many studies have shown a correlation between depression symptoms in patients and low levels of zinc. Recently, more research has focused on the supplementation of zinc with antidepressants for depression. Chandagari J., et al  in an extensive review article evaluated 50 research and review articles published from 1979 to 2025 and found support for zinc as a potential adjunctive therapeutic supplement for patients with major depressive disorder, particularly in the elderly. (8)

Vitamin D

Vitamin D is needed for adequate production of serotonin and dopamine and has anti-inflammatory actions. So it is not surprising that it plays a role in multiple psychiatric conditions. A randomized, placebo-controlled, double-blind clinical trial was conducted with 224 adults diagnosed with major depressive disorder who were given 50,000 IU of vitamin D weekly for 6 months. Vitamin D supplementation significantly increased serum concentrations to adequate physiological levels and led to statistically significant marked reductions in depressive symptoms and suicide risk. Additionally, 13 of 15 evaluated cardiovascular risk factors showed normalization or significant reductions, including better lipid profiles, glycemic control, and inflammatory markers. Clinically, these findings suggest potential for vitamin D as an adjuvant therapy in depression management, contributing to both mental health and cardiometabolic stability. (9)

Vitamin D levels have also shown a relationship to ADHD, but results have been inconsistent. A  2025 meta-analysis and review of 30 observational studies and 7 RCTs, with a combined sample of 24,336 participants, found that children and adolescents with ADHD have lower mean concentrations of serum Vitamin D  than healthy controls. Furthermore, the meta-analysis of prospective studies indicated that perinatal vitamin D status is significantly associated with risk of ADHD in childhood or adolescence. (10)

B Vitamins

Deficiencies in B vitamins, particularly vitamins B9 (folate) and B12 (cobalamin), have significant neuropsychiatric manifestations that can profoundly impact mental and neurological health. These deficiencies are implicated in a wide array of conditions, including depression, OCD, cognitive decline, psychosis, peripheral neuropathy, and myelopathy. The underlying mechanisms involve critical biochemical processes such as DNA synthesis, methylation reactions, neurotransmitter production, and myelin synthesis, all of which are essential for the proper functioning and maintenance of the nervous system. A 2025 meta-analysis explored the roles of vitamins B9, B12, and D, as well as genetic variants associated with the development of depression. Deficiencies in vitamins B9 (folate) and B12 (cobalamin) were associated with more severe depressive symptoms, longer episodes, and decreased treatment responsiveness. Genetic variants, particularly in the MTHFR gene, were associated with a significant influence on individual susceptibility to depression.(11) A case control study comparing serum B12 and folate levels in patients with OCD versus controls found significantly lower B12 levels in patients with OCD and positive correlation between B12 levels and severity of OCD symptoms. Serum folate levels did not differ significantly between the groups. (12)

Iron

Clinically we often see children with low ferritin- an indication of low iron stores- without anemia or low serum iron. Lower levels of ferritin have been observed in children with ADHD compared to non-ADHD peers. A modest database and anecdotal clinical experience show that iron supplementation can still be helpful in children with ADHD even without the presence of anemia due to iron’s impact on dopamine synthesis. Pediatricians generally do not check ferritin levels unless anemia is present.

A systematic review by Khattab, RA et al,  updated the current evidence on the effects of iron supplementation on cognitive development and school achievement of school-age children.(13) I was hoping this paper would be a call to action to check for and treat low ferritin in children without anemia but results are mixed and the data showed cognitive improvements primarily in the children with low ferritin and anemia. There is clearly a need for more research in this area to improve clinical guidance in this area. One of the dilemmas is that even though serum ferritin is on average lower in ADHD, peripheral levels of ferritin may not reflect brain levels which could be pertinent particularly in children without other signs of iron deficiency.

GENETICS

Anxiety

Fang, X. et al (14) found suggestive genetic evidence of the protective role of vitamin C, magnesium, and selenium on the risk of anxiety and support targeting anxiety phenotypes with nutritional interventions. These findings suggest that inherent or acquired deficiencies of these micronutrients may be involved in the pathogenesis of anxiety disorders and that supplementing their levels may alleviate anxiety symptoms and, possibly, prevent their onset.

ADHD

Dixit, A. et al, performed a systematic review on the  interaction between nutrient status, gene polymorphisms, and environmental exposures in the development and progression of ADHD. (15) They found strong evidence that variants in genes like MTHFR, SLC6A3 (DAT1), FADS2, and DRD4 influence neurodevelopmental trajectories by affecting methylation, fatty acid metabolism, and dopamine signalling and that  these genetic susceptibilities are modulated by dietary intake of folate, zinc, iron, and omega-3 fatty acids. Environmental factors—such as sleep disruption, excessive screen time, and ultra-processed food consumption—may lead to behavioural phenotypes that mimic or amplify ADHD symptoms.

LIFESTYLE

Meditation

A simplified mindfulness meditation in a group of 6-9 year olds on medication for ADHD led by  their parents  for 21 days reduced core ADHD symptoms and enhanced social functioning while also reducing parental anxiety and improving family interactions compared to a control group of medication only. (16) The authors suggest some easy practical ways to integrate this simple training in multiple settings including outpatient clinics, hospital units and schools.

METABOLIC PSYCHIATRY

Diet

Increasing evidence suggests that poor metabolic health, including insulin resistance and/or metabolic syndrome, may increase the risk of depression and that a ketogenic diet may be an effective treatment strategy.

A pilot study by Decker, D.D. et al, (17)  suggests that a well-formulated ketogenic diet may be feasible as an adjunct therapy for college students with major depressive disorder. A whole foods ketogenic diet for 10-12 weeks. In students with mild to moderate depression,  Significant improvements in symptoms were observed, as evidenced by a 69% reduction in PHQ-9 and a 71% reduction in HRSD. There were also improvements in leptin and BDNF levels and improvement on a battery of cognitive tests. Although this was a small sample with no control group, the results were impressive and we can expect more research in this area in the future to guide clinical care.

A case study by Bellamy ,L.L. et al, (18) in a 38 yo woman with  PTSD, ADHD, BED, bipolar II disorder, depression, anxiety, and premenstrual dysphoric disorder completed an 8 week ketogenic diet and all psychiatric symptoms completely resolved when ketone levels were maintained between 3 nad 5 mmol/L. Baseline measures were in the severe range. This is an important case study because the significant co-morbidity and severity of initial symptoms reflects the complexity of patients showing up in our offices and hospitals. This report demonstrates the potential of a ketogenic diet  to achieve comprehensive remission in severe, treatment-resistant psychiatric comorbidities.

Gut Microbiome

Anorexia Nervosa (AN) is the most lethal condition we treat in psychiatry and we desperately need an expanded understanding of underlying root causes to improve treatment strategies and outcomes. Gabriel-Segard, T. et al (19) in a mouse model demonstrated that the transfer of AN microbiota induced behavioral, physiological, and organ-level alterations seen in patients with AN including food restriction, anxiety-like behavior, physical hyperactivity, and elevated inflammatory responses. Likewise, organ-specific alterations associated with AN, such as liver dysfunction and disruption of ovarian follicles, were also reproduced. Although this does not address the issue of whether these microbiota changes preceded the development of AN or are a consequence of the disorder, at a minimum these results suggest the altered microbiome is a maintenance factor and should be considered in treatment planning.

The Year Ahead: Functional Psychiatry in 2026

There is growing interest in the biomedical underpinnings of psychiatric conditions among the public, clinicians, and psychiatric leadership, driven in part by the recognized limitations of current diagnostic systems that rely primarily on symptom clusters and pharmacologic treatments. Historically, a significant lag has existed between advances in basic science and their translation into clinical practice. This gap can be narrowed through evidence-based training programs that bring emerging science into clinical care.

Psychiatry Redefined offers year-long Adult and Pediatric fellowships designed to address this training gap. We believe this approach represents a critical component of the future of psychiatry, and it is encouraging to see growing momentum toward complementing existing paradigms with personalized, biomedically informed treatment models.